+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Overactive Bladder Drug"

From
From
From
From
Darifenacin Hydrobromide Market in India - Product Thumbnail Image

Darifenacin Hydrobromide Market in India

  • Report
  • February 2026
  • 150 Pages
  • India
From
Darifenacin Hydrobromide Market in Germany - Product Thumbnail Image

Darifenacin Hydrobromide Market in Germany

  • Report
  • February 2026
  • 150 Pages
  • Germany
From
Darifenacin Hydrobromide Market in Canada - Product Thumbnail Image

Darifenacin Hydrobromide Market in Canada

  • Report
  • February 2026
  • 150 Pages
  • Canada
From
Darifenacin Hydrobromide Market in China - Product Thumbnail Image

Darifenacin Hydrobromide Market in China

  • Report
  • February 2026
  • 150 Pages
  • China
From
From
From
From
Loading Indicator

The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations. The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more